PHAR: Rega marang dodolan Pharming
Pharming Group N.V. relies on patent protection and sales of treatments for hereditary angioedema, although the company is currently successfully reducing its dependence on a single product through new immune drugs. The company's rolling P/S visualizes this transformation, with the indicator reaching 2.40. Strategic alliances with research centers and the licensing of therapies are accelerating the global market entry of orphan drugs.
Rincian metrik lan analitis perusahaan Pharming (PHAR)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- data nilai buku modal saham:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Pharming Group N.V.|PHAR - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Pharming Corp|PHAR - Utang perusahaan|Utang marang nilai buku Pharming|PHAR - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Pharming Group|Rasio likuiditas darurat pharming.com
- indikator bathi lan kelipatan valuasi:
PHAR - Bathi resik|Proyeksi bathi resik Pharming Group N.V.|PHAR - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi Pharming Group NV|PHAR - Pangali PEG|Pangali nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Pharming|PHAR - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Pharming Group|PHAR - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan pharming.com|PHAR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep Pharming Group N.V.
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:PHAR (pharming.com)
The stability of Pharming Group N.V. (PHAR) is based on the lifelong demand from insurers for high-cost drugs used to treat rare pathologies. The P/S ratio compares market capitalization to annual revenue, allowing the price-to-sales trend to determine the extent of the asset's overvaluation and assess the long-term effectiveness of monetizing patented biological developments.
Perusahaan pesaing
argenx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rega marang dodolan|ADMA - Rasio rega marang pendapatan|Rasio rega marang dodolan PTGX|IMVT: Multiplikator P/S|kiniksa.com - Rasio kapitalisasi pasar marang pendapatan|GRFS (Grifols) - Multiplikator P/S|Multiplikator P/S Adaptive Biotech|Rasio rega marang pendapatan Celldex (CLDX)|AUPH (Aurinia Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan BioCryst BCRX|VERA - Kapitalisasi marang pendapatan|Dianthus Therapeutics, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Pharvaris NV PHVS|AbCellera Biologics Inc (ABCL) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan TRML|PGEN (Precigen, Inc.) - Multiplikator P/S|NKTR - Multiplikator rega marang pendapatan|Kapitalisasi marang pendapatan UPB (Upstream Bio)|ZBIO (Zenas Bio) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S IMNM (Immunome Corp)|Multiplikator rega marang pendapatan Gossamer Bio Corp.|KALV - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SEPN (septerna.com)|Pieris Pharmaceuticals, Inc. (PVLA) - Rasio rega marang pendapatan|Rega marang dodolan Savara Inc (SVRA)|Kapitalisasi marang pendapatan RIGL|Multiplikator P/S AnaptysBio Inc.|Rasio rega marang pendapatan Astria Therapeutics (ATXS)|ENGN: Rasio rega marang dodolan|RAPT Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan JBIO|ACRS - Rasio rega marang pendapatan|KYTX (Kyverna Therapeutics, Inc) - Rasio kapitalisasi marang pendapatan|TLSA (Tiziana Life Sciences) - Kapitalisasi marang pendapatan|CABA - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan VTYX|Rasio rega marang pendapatan THTX|Kapitalisasi marang pendapatan AVTX (Avalo Therapeutics Inc.)|Koefisien rega marang pendapatan Eledon Pharmaceuticals, Inc|Rasio rega marang pendapatan Agenus AGEN|CLYM (climbbio.com) - Rasio rega marang dodolan|Zura Bio - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan ATYR (aTyr Pharma Inc)|ADAG: Multiplikator P/S|Ikena Oncology (IMA) - Multiplikator P/S|Rasio rega marang pendapatan Shattuck Labs Inc|EQ: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Connect Biopharma (CNTB)|IMUX: Rasio rega marang dodolan|Multiplikator P/S ATRA (Atara Bio)|Rasio kapitalisasi pasar marang pendapatan IFRX|X4 Pharmaceuticals - Multiplikator P/S|ACET - Multiplikator P/S|celularity.com (CELU) - Rasio rega marang pendapatan|INmune Bio Inc - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Barinthus Bio|Kapitalisasi marang pendapatan Kezar Life Sciences Inc (KZR)|Multiplikator P/S SABS|Multiplikator P/S akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan QTTB|GeoVax Labs Inc - Multiplikator P/S|Koefisien rega marang pendapatan Edesa Biotech Corp EDSA|iBio, Inc. (IBIO) - Rasio rega marang pendapatan|Kapitalisasi marang pendapatan Carisma Therapeutics Inc.|Rasio rega marang pendapatan XTL Biopharmaceuticals Ltd.|Kapitalisasi marang pendapatan Bolt Bio (BOLT)|Kapitalisasi marang pendapatan HCWB (HCW Biologics Inc.)|Multiplikator P/S aptevotherapeutics.com (APVO)|Rasio rega marang pendapatan AIM ImmunoTech Inc. AIM|ADTX: Rasio kapitalisasi marang pendapatan|GRI Bio - Multiplikator P/S|Rega marang dodolan XORTX Therapeutics Inc|ReShape Lifesciences (HIND) - Rasio rega marang pendapatan|Rasio rega marang dodolan REVB (Revelation Biosciences Corp)|INDP (Indaptus Therapeutics) - Multiplikator P/S|SCNI: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CALI|Multiplikator P/S affimed.com (AFMD)|Rasio rega marang pendapatan Allakos ALLK|Rasio kapitalisasi pasar marang pendapatan HOOK|IGMS - Rasio rega marang pendapatan|iteostherapeutics.com (ITOS) - Kapitalisasi marang pendapatan|OCEA: Multiplikator P/S|TCBP - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Third Harmonic Bio, Inc
